Sartorius sets up for the next earnings round, shares tracked in the MDAX
26.06.2026 - 11:53:30 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 11:53.
Sartorius (DE0006292006) is one of the larger life sciences equipment names in the German MDAX and trades in Frankfurt on Xetra. The group is closely watched by investors ahead of its next quarterly figures, when trends in bioprocessing demand will again be scrutinized.
What consensus expects next
Sell-side consensus for Sartorius typically clusters around mid to high single-digit annual revenue growth over the medium term, reflecting normalizing demand after the pandemic-related spike. Many analysts continue to see the company as a key beneficiary of structural growth in biologic drugs and cell and gene therapies.
On the earnings side, margins are expected to stabilize as Sartorius digests recent capacity expansions and adjusts to a more normal order intake. Investors often compare the rating and growth assumptions with peers such as Merck KGaA and Thermo Fisher Scientific when assessing valuation.
How the stock is positioned in Europe
As a supplier of filtration, fermentation and single-use technologies, Sartorius sits in the life sciences tools segment rather than in pharmaceuticals itself. The shares are part of the MDAX, giving the stock a role in many European mid-cap and sector-focused indices and ETFs.
Compared with broader European industrial names, Sartorius is more exposed to long-term spending on biologics manufacturing, quality control and laboratory automation. This positioning means that sentiment often follows announcements on biologic pipeline investments and capacity plans by large pharmaceutical and biotech groups.
More news and background on the Sartorius shares
All current reports, background pieces and market data on the Sartorius listing are bundled in the topic area on ad-hoc-news.de.
How Sartorius makes its money
Sartorius generates most of its revenue with equipment and consumables for biopharmaceutical production and laboratory work. Key offerings include single-use bioreactors, filters, chromatography systems and precision laboratory balances that support customers from research to large-scale biologics manufacturing.
Where the shares trade today
The Sartorius shares (DE0006292006) trade in euros on Xetra in Frankfurt; the latest available price data on 2026-06-26 should be taken from the current Xetra quotation before making any investment decision.
Key data on the Sartorius shares
- Company: Sartorius AG
- ISIN: DE0006292006
- WKN: 716563
- Ticker: SRT
- Trading venue: Xetra
- Price (as of 2026-06-26, 11:53): [check latest Xetra quote] EUR
- Market cap: [check latest figure] EUR (as of 2026-06-26)
- Sector / industry: Life sciences tools and services
- Index membership: MDAX
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources considered reliable; completeness and accuracy cannot be guaranteed.
